| Theme |
Recent advance in the treatment of IBD based on the pathogenesis |
| Title |
α4β7 integrin treatment for inflammatory bowel disease |
| Author |
Shunichi Yanai |
Division of Gastroenterology, Department of Internal Medicine, Iwate Medical University |
| Author |
Takayuki Matsumoto |
Division of Gastroenterology, Department of Internal Medicine, Iwate Medical University |
| [ Summary ] |
Anti-TNF therapy has become an essential treatment for inflammatory bowel disease. Recently, biologics targeting other cytokines and adhesion molecules have been developed. Vedolizumab is a biologic, which inhibits α4β7 integrin-MAdCAM-1 interaction, and as a consequence, inhibits recruitment of lymphocytes in tissue. Since MAdCAM-1 is specifically expressed in the venules and lymphoid tissues of the gastrointestinal mucosa. The action of vedolizumab is believed to be gut-selective. Large clinical trials have shown that vedolizumab is effective and safe for the induction and maintenance of clinical remission in patients with ulcerative colitis and Crohn's disease. Thus it seems possible that vedolizumab is a novel and alternative therapy for patients with intractable inflammatory bowel disease. |